🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06759116
Recruiting Not applicable

Comparison Between Fentanyl and Dexmedetomidine As Adjuvant to Bupivacaine in Combined IPACK and Adductor Canal Block for Postoperative Analgesia After Knee Surgeries

NCT06759116 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-01-10
Last updated
2025-01-14

Condition(s) studied

Analgesia, Postoperative

Investigational drug(s) / intervention(s)

Control groupFentanyl groupDexmedetomidine group

Control group: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ml saline)

Fentanyl group: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 50 mcg fentanyl)

Dexmedetomidine group: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ug/kg dexmedetomidine not exceeding 100 ug (to be completed to 1mL with normal saline if needed). )

Study summary

This study will be undertaken to compare the analgesic effects of of fentanyl versus dexmedetomidine as adjuvant to bupivacaine in combined IPACK and ACB for pain management after total knee arthroplasty.

Eligibility

Sex
ALL
Min age
21 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1 - Patient acceptance 2. Cooperative patients 3. Age: ≥21 and 85\< years' old 4. Sex: both sexes (males or females). 5. Physical status: ASA Ι \& II\& Ш. 6. Body Mass Index (BMI): ≤ 35 kg/m2. 7. Type of operation: elective unilateral knee surgeries (TKA, ACL, knee arthroscopy) Exclusion Criteria: . Patient with any contraindications of regional blocks (as coagulopathy or local infection at injection site) 2. Patients with known history of allergy to the study drugs (bupivacaine, dexmedetomidine and fentanyl). 3\. Advanced hepatic, renal, cardiovascular, neurologic and respiratory diseases. 4.Chronic opioid use (more than 3 months or daily oral morphine \> 5 mg /day for 1 month) \-

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
faculty of human medicine, Zagazig university hospitals El Sharkia Egypt Recruiting

More Zagazig University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06759116 on ClinicalTrials.gov ↗ ← All trials in Egypt